Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a...  More >>

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
- Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa - Post-treatment Endpoint Results to be Discussed with Regulatory Agencies PALO ALTO, Calif. , April 11, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and
Toggle Summary Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago
PALO ALTO, Calif. , April 24, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced that an abstract describing prevalence of hepatitis delta virus (HDV) in the U.S. will be presented at Digestive Disease Week (DDW) in Chicago, Illinois , May 6 to 9, 2017 .
Toggle Summary Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif. , Oct. 2, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced that two abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Washington DC , October 20 to 24, 2017 .
Toggle Summary Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting
PALO ALTO, Calif. , March 5, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program will be presented at The International Liver Congress™ meeting in Paris, France ,
Upcoming EventsMore >>
More events are coming soon.
What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.